Nexium Maker Wants Antitrust Claims Handled By Patent Judge

Law360, Dallas (November 29, 2012, 12:00 AM EST) -- AstraZeneca PLC argued Thursday before the U.S. Judicial Panel on Multidistrict Litigation that putative antitrust class actions alleging it wrongly kept generic versions of its Nexium drug off the market should be consolidated and heard by the federal judge who heard an earlier Nexium patent case.

U.S. District Court Judge Joel A. Pisano, who approved settlement agreements in the patent case and signed an injunction that keeps generic versions of the heartburn drug off the market until 2014, has a background and familiarity with the drug...
To view the full article, register now.